Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis? (SELECT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01740947|
Recruitment Status : Terminated (Superiority was no longer attainable)
First Posted : December 4, 2012
Last Update Posted : November 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)||Phase 4|
Infectious complications and especially anastomotic leakage severely impede the recuperation of patients following colorectal cancer surgery. When the normal gut barrier fails such as in anastomotic leakage, pathogenic microorganisms like Gram-negative bacteria enter the circulation and may cause severe sepsis which is associated with considerable mortality. Moreover, anastomotic leakage has a negative impact on colorectal cancer prognosis. Selective decontamination of the digestive tract (SDD) is a prophylaxis regimen that employs oral nonabsorbable antibiotics to eradicate pathogenic micro-organisms like Gram-negative bacteria.
The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve. Secondary objectives are a decline in reoperation rate, in-hospital mortality, readmission rate, duration of hospital stay and ICU admission, non-infectious complications, improvement of quality of life and reduction of costs.
A randomised multicenter clinical trial comparing perioperative SDD in addition to standard antibiotic prophylaxis with standard antibiotic prophylaxis alone in patients with colorectal cancer who undergo elective surgical resection with curative intent.
Patients 18 years or older are eligible for inclusion when they are diagnosed with colon or rectal cancer without signs of distant metastases. Patients may be scheduled for either laparoscopic or open resection with curative intent, including construction of an anastomosis (either with or without diverting stoma). Patients are not eligible for inclusion in case of concomitant metastases or acute obstruction.
Patients are randomly allocated for either perioperative SDD (intervention group) including standard antibiotic prophylaxis or standard treatment (including standard antibiotic prophylaxis alone) (control group). The solution containing SDD is orally taken 4 times daily, starting 3 days before surgery and continued until normal bowel passage or at least 3 days after surgery. Both groups receive a single preoperative intravenous dose of 1000 mg Cefazoline and 500 mg Metronidazole, which is the current standard antibiotic prophylaxis.
Main study parameters/endpoints:
The main study parameter is anastomotic leakage. The research hypothesis refers to an estimated decrease in anastomotic leakage rate in the SDD treated group (from 9% to 4%). As anastomotic leakage has been shown unfavourable forlong term oncological outcome, we presume an improvement in disease free survival, which serves as important secondary endpoint.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||485 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||March 2017|
|Actual Study Completion Date :||March 2017|
No Intervention: Standard treatment
Standard treatment for colorectal cancer
Experimental: Selective decontamination of the digestive tract (SDD)
Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.
SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively.
Drug: Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)
SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
Other Name: SDD
- anastomotic leakage and/or abscess [ Time Frame: 30 days postoperatively ]clinical and/or radiological evidence of anastomotic dehiscence requiring surgical or radiological (re)intervention.
- Disease free survival [ Time Frame: 3 and 5 years after inclusion ]
- Other postoperative infectious complications [ Time Frame: 30 days postoperatively ]pneumonia, urinary tract infections, surgical site infections, wound dehiscence, (remote) intraabdominal abscess
- Non-infectious complications [ Time Frame: 30 days postoperatively ]cardiac failure, cerebrovascular events, deep venous thrombosis
- In-hospital mortality [ Time Frame: 30 days postoperatively ]
- Readmission rate [ Time Frame: 5 years postoperatively ]
- Reoperation rate [ Time Frame: 5 years postoperatively ]
- Duration of hospital stay [ Time Frame: 30 days postoperatively ]
- Quality of life (quality adjusted life years) [ Time Frame: 2 years postoperatively ]
- In hospital and out-of-hospital costs [ Time Frame: 5 years postoperatively ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01740947
|VU University Medical Center|
|Principal Investigator:||H.J. Bonjer, Md, PhD, FRCSC||VU University Medical Center|
|Study Director:||G.S.A. Abis, MD, MSc||VU University Medical Center|